Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

The sNDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025. RTOR allows ...

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in ...

The upcoming sNDA submission will be based on data from the Phase 3 DUPLEX and Phase 2 DUET studies, which are among the largest interventional studies conducted for FSGS to date. The company's ...

Review which funds and institutions currently hold Sunda Energy PLC (SNDA:XLON) stock for ownership information.

Such forward-looking statements include, but are not limited to, references to: statements regarding the FDA’s review of the Company’s sNDA for FILSPARI in FSGS, and expectations regarding the ...

--Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New ...

The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profile CAPLYTA, if approved as ...